Agoracom Blog Home

Posts Tagged ‘tsx-v’

Binovi $VISN.ca $BNVIF Appoints Dr. Michael Gallaway to the Binovi Scientific Advisory Board $EYPT $KALA $PTON $WELL.ca $DOC.ca $DOCRF

Posted by AGORACOM-JC at 10:23 AM on Tuesday, December 22nd, 2020
  • Announced the appointment of Dr. Michael Gallaway to the Binovi Scientific Advisory Board. Dr. Galloway joins the other members of the board in directing the company’s advancements.
  • “We are very pleased to welcome Dr. Gallaway to the Scientific Advisory Board. His extensive experience working with children will help tremendously as we push Binovi into the education sector, with our focus on K-12 -and particularly K-3-students,” said Adam Cegielski, Binovi CEO.

TORONTO, ON and NEW YORK, NY / December 22, 2020 / Binovi Technologies Corp., (Binovi) (OTCQB:BNVIF) (TSX-V:VISN) (GR:2EYA) is proud to announce the appointment of Dr. Michael Gallaway to the Binovi Scientific Advisory Board. Dr. Galloway joins the other members of the board in directing the company’s advancements.

“We are very pleased to welcome Dr. Gallaway to the Scientific Advisory Board. His extensive experience working with children will help tremendously as we push Binovi into the education sector, with our focus on K-12 -and particularly K-3-students,” said Adam Cegielski, Binovi CEO.

“I am delighted that Dr. Gallaway has joined our Scientific Advisory Board”, commented Dr. Leonard Press, Binovi Chief Scientific Officer. “His background in scientific research, vision-based learning problems, vision screening, and concussion management, will help take Binovi to another level.”

“I look forward to joining Binovi’s Scientific Advisory Board especially as the company is targeting more advanced school screening protocols and interventions for children,” said Dr. Gallaway, Binovi Scientific Advisory Board Member.

About Dr. Michael Gallaway

Dr. Gallaway is board certified in vision therapy as a Fellow in the College of Optometrists in Vision Development (COVD), and is a Fellow in the American Academy of Optometry (AAO). He has been in private practice in the South Jersey area since 1989, specializing in vision therapy and children’s vision disorders. He is also an Associate Professor at the Pennsylvania College of Optometry at Salus University in Philadelphia. In addition to his teaching, he is involved in research in learning related vision problems, amblyopia, vision therapy for convergence insufficiency, and concussion-related vision problems. He has published many articles in optometric journals and has lectured extensively in the US and internationally on children’s vision and vision therapy.

Dr. Gallaway was the Principal Investigator at Salus/PCO for CITT-ART, a National Eye Institute funded nationwide study assessing the impact of vision therapy for convergence insufficiency on reading and attention. In 2015, Dr. Gallaway received the Skeffington Award for Excellence in Optometric Writing from the College of Optometrists in Vision Development in recognition of his scholarly writing and research over his career. Dr. Gallaway was also the Principal Investigator at Salus University for the Convergence Insufficiency Treatment Trial (CITT), an NIH funded randomized multicenter clinical trial that was published in 2008.

Dr. Gallaway was also an Investigator both in his office and at Salus University for the Pediatric Eye Disease Investigator Group (PEDIG) studying the Amblyopia Treatment Studies, which Dr. Gallaway has participated in from 2001 to 2019.

For additional information on the Company, please visit https://www.binovi.com/binovi-connect

@BinoviVISN – Twitter & Instagram

About Binovi Connect

Binovi is digitizing the delivery of healthcare by providing users access to all points of their individual performance from their phone, tablet or desktop computer. Designed for vision optimization and the enhancement of skills related to cognitive performance, Binovi provides measurable results in less time, and with less effort. As a SAAS based solution, the Binovi Connect App is supported by specialized expert knowledge, unique data insights and supporting hardware to deliver customized, one-on-one cognitive training and learning protocols ideal for K-12 Students, Vision Care Specialists, and Sports Performance testing and training. Binovi is currently used in over 20 countries.

Terry Booth
Executive Chairman

Adam Cegielski
Founder | CEO

Dr. Leonard Press
Chief Scientific Officer

Investor Relations

Email: [email protected]
Toll-free: 1 (844) 866-6162
https://www.binovi.com/investor-reports/

Forward looking information:

Certain statements contained in this news release constitute “forward-looking information” as such term is used in applicable Canadian securities laws. Forward-looking information is based on plans, expectations and estimates of management at the date the information is provided and is subject to certain factors and assumptions, including, that the Company’s financial condition and development plans do not change as a result of unforeseen events and that the Company obtains regulatory approval. Forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause plans, estimates and actual results to vary materially from those projected in such forward-looking information. Factors that could cause the forward-looking information in this news release to change or to be inaccurate include, but are not limited to, the risk that any of the assumptions referred to prove not to be valid or reliable, that occurrences such as those referred to above are realized and result in delays, or cessation in planned work, that the Company’s financial condition and development plans change, and delays in regulatory approval, as well as the other risks and uncertainties applicable to the Company as set forth in the Company’s continuous disclosure filings filed under the Company’s profile at www.sedar.com . The Company undertakes no obligation to update these forward-looking statements, other than as required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Binovi Technologies Corp.

VIDEO – ImagineAR $IP.ca $IPNFF Racks Up Big Name Wins In 2020. With Big Cash On Hand, CEO Expects Another Big Year In 2021 $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

Posted by AGORACOM-JC at 8:00 PM on Sunday, December 20th, 2020
http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg

As the name implies, ImagineAR (IP:CSE / IPNFF:OTCQB) is an Augmented Reality Company … but they’re not just any AR company.  Imagine enables businesses to create their own mobile phone AR campaigns with no programming or technology experience. Why is that important?  Ask Apple CEO Tim Cook who stated

“AR Will play an important role in how we use technology in the future – and promises to be as influential in our society as the smart phone”  

For those of you that are just discovering Augmented Reality, “AR” is essentially a technology that lays digital images and graphics over the real world, typically by looking through your cell phone or special glasses.  If you think it sounds like a gimmick, it isn’t.  AR will create an entire new revenue stream for businesses, organizations and sports teams that will boggle the mind in the next 3 years.

ImagineAR provides small cap investors with an opportunity to participate in the growth of this mega market in the making …. and they they signed the MASSIVE brand contracts in 2020 to prove it:

DECEMBER 10 – ImagineAR Announces Agreement with Indian Superstar Singer Ananya Birla

NOVEMBER 25 – ImagineAR Signs Two Year Partnership Agreement with Real Sociedad of La Liga To Provide Interactive Augmented Reality Experiences for Fans

NOVEMBER 20 – ImagineAR to Deliver Immersive AR Conference Experience for Shoppers Drug Mart

  “Shoppers Drug Mart is thrilled to be the global pioneer in integrating mobile augmented reality with virtual events.”  (Karen Bossion, Director Conferences & Events)  

SEPTEMBER 30 – ImagineAR Signs Two-Year Agreement with Valencia C.F. Of La Liga To Provide Interactive Augmented Reality Experiences for Almost 7 Million Fans Around The World

SEPTEMBER 24 – NFL Alumni Academy and ImagineAR Sign 5 Year Partnership Agreement

We could go on but you get the pont …. and some of the smartest people in sports agree the Company is a best of breed company:

image.png
image.png

“In my 30 years working in sports and entertainment technology, I have never seen a solution that provides such a high level of interaction & engagement”  (Chris Dill)

“The ImagineAR platform is years ahead of every other company today” (WaV Sports)”

“ImagineAR has one of the most amazing mobile technologies I have seen to date” (Gus Frerotte)

“The ImagineAR augmented reality platform is truly a gamechanger for sports organizations and athletes to deliver in-home mobile phone engagement” (WaV Sports)

2020 was a great year and a major turning point for ImagineAR and sets up the Company for an ever far better 2021 … which explains why our latest interview with CEO Alen Paul Silverrstieen is by far the best one of the year.  

Universal PropTech $UPI.ca Announces the Appointment of Robert Daniels to the Advisory Board $SNE $MSFT $HON

Posted by AGORACOM-JC at 8:38 AM on Friday, December 18th, 2020
  • Announced the appointment of Mr. Robert Daniels to the Advisory Board
  • Mr. Daniels is a long-time creator and developer of new business ventures and initiatives in the real estate and sustainability fields.
  • With a career spanning over 30 years, Mr. Daniels has been involved in substantial multi-million-dollar ventures in real estate and land development, commercial property investment and renewable power totalling over $1.4 B.
  • As an industry leader, he became one of the first large-scale builders of super energy efficient homes in Canada and one of the first independent full-scale retailers of environmentally responsible products.

Toronto, Ontario–(December 18, 2020) – Universal PropTech Inc. (TSXV: UPI) (“UPI” or “the Company”) is pleased to announce the appointment of Mr. Robert Daniels to the Advisory Board.

Mr. Daniels is a long-time creator and developer of new business ventures and initiatives in the real estate and sustainability fields. With a career spanning over 30 years, Mr. Daniels has been involved in substantial multi-million-dollar ventures in real estate and land development, commercial property investment and renewable power totalling over $1.4 B. As an industry leader, he became one of the first large-scale builders of super energy efficient homes in Canada and one of the first independent full-scale retailers of environmentally responsible products.

Mr. Daniels is a former board member of the Greater Toronto Home Builders Association, the Urban Development institute and numerous private companies and charitable organizations in Ontario. He is a graduate of The Wharton School of Business at the University of Pennsylvania. As a Climate Reality Leader, he holds a certification in ISO-14064-3: GHG Validation and Verification from the University of Toronto.

Mr. Daniels will support the Company’s efforts in investments and acquisitions of PropTech companies together with overall business development knowledge of commercial, institutional and multi-residential asset owners and managers.

“I have been a serial entrepreneur my entire life. I understand the leadership required to not only make deals, but to make them successful, and I have joined as an Advisor because I believe that this type of participation can do just that to help with Universal PropTech’s strategy,” commented Robert Daniels, Advisor, Universal PropTech Inc.

“We are excited to have Bob support us in our growth campaign to acquire, invest and license PropTech,” stated Chris Hazelton, Chief Executive Officer of Universal PropTech Inc. “His development and investment experiences will be of tremendous value going forward.”

About Universal PropTech Inc.

Universal PropTech Inc. (TSXV: UPI) is a leading building innovation company, selecting, integrating, deploying and maintaining PropTech in healthy buildings. As trusted advisors, we provide holistic evidence-driven solutions and services for building developers, owners and operators in Canada.

UPI operates through its wholly owned subsidiary, VCI Controls Inc. (“VCI”), a leading supplier and integrator of PropTech healthy building solutions and services. VCI is an industry leader in the acquisition and deployment of intelligent building technology, including the integration of all building systems utilizing the latest in communications technologies and standards. VCI’s business focuses on digital controls and mechanical services, performance monitoring, and energy efficiency solutions.

With headquarters in Toronto, Universal PropTech has offices across Canada including, Halifax, Montreal, and Ottawa. For more information, visit www.universalproptech.com.

Certain statements in this press release are forward-looking statements. The reader is cautioned that assumptions used in the preparation of such information, although considered reasonable by the Company at the time of preparation, may prove to be incorrect. Forward-looking statements, specifically those concerning future performance and other statements that are not historical fact, are subject to certain risks and uncertainties, and actual results may differ materially from the Company’s plans and expectations. These plans, expectations, risks and uncertainties are detailed herein and from time to time in the filings made by the Company with the TSX Venture Exchange (the “Exchange”) and securities regulators. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Trading in the securities of the Company should be considered highly speculative. All forward-looking information contained in this news release is expressly qualified in its entirety by this cautionary statement.

Neither the Exchange, nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

CONTACT INFORMATION

Universal PropTech Inc.
Chris Hazelton
Chief Executive Officer
(647) 300-2957

Empower Clinics $CBDT.ca $EPWCF Signs Definitive Agreement to Acquire Momentum Health With 7 Canadian Clinics. Begins Planning for Nationwide Rollout $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 4:16 PM on Thursday, December 17th, 2020

Acquisition Will Expand Company’s North American Footprint And Strengthen Vertical Integration From Patients To Laboratory, Strengthening Testing and Bubble Initiatives

  • Announced the execution of a definitive share purchase agreement dated December 16, 2020 to acquire Lawrence Park Health and Wellness Clinic Inc., 1100900 Canada Inc. dba Atkinson, and Momentum Health Inc.
  • Momentum Health operates a network of medical clinics with a team of healthcare professionals who provide para-medical care by applying a holistic and hands-on approach working with patients to unlock potential well-being.
  • Key services include physiotherapy, chiropractic, massage therapy, traditional Chinese medicine, athletic therapy and others.
  • Acquisition will include two standalone wellness clinics and five new co-located clinics in the Greater Toronto Area of Ontario, Canada, with immediate access to in excess of 20,000 patients.

VANCOUVER, BC / December 17, 2020 / Empower Clinics (CSE:CBDT)(OTC PINK:EPWCF)(FRA:8EC) (the “Company” or “Empower”), an integrated healthcare company serving patients through clinics, a telemedicine platform, and a leading medical diagnostics laboratory processing thousands of COVID-19 specimens and developing novel COVID-19 testing protocols for CE, FDA and Health Canada approval, is pleased to announce the execution of a definitive share purchase agreement dated December 16, 2020 (the “Agreement“) to acquire Lawrence Park Health and Wellness Clinic Inc., 1100900 Canada Inc. dba Atkinson, and Momentum Health Inc. (collectively “Momentum Health“).

Steven McAuley, Chairman and CEO of Empower stated “The acquisition of Momentum Health will be a significant milestone for both Empower and its shareholders that we expect will provide Empower with a growing accretive business, as well as, a winning business model with plans for immediate expansion across the Greater Toronto Area, the province of Ontario and then nationwide in very rapid succession. It is anticipated that this immediate and rapid nationwide expansion plan will be made possible by combining the winning Momentum Health model with the financial, marketing and operational control resources already successfully deployed by Empower in building its US operations, including the successful win of a $1.2 million testing contract with a film and television studio within just 45 days of acquiring our KAI Medical Lab. Significant discussions are already underway with potential nationwide partners and we expect to have developments in the very near future.”

ACQUISITION INCLUDES 7 CLINICS IN GREATER TORONTO AREA WITH IMMEDIATE PLANS TO EXPAND “CLINIC-IN-CLINIC” MODEL ACROSS CANADA.

Momentum Health operates a network of medical clinics with a team of healthcare professionals who provide para-medical care by applying a holistic and hands-on approach working with patients to unlock potential well-being. Key services include physiotherapy, chiropractic, massage therapy, traditional Chinese medicine, athletic therapy and others. The full range of services can be viewed at www.momentumhealthclinic.com.

The acquisition will include two standalone wellness clinics and five new co-located clinics in the Greater Toronto Area of Ontario, Canada, with immediate access to in excess of 20,000 patients.

More importantly, it is expected that expansion will be at a very attractive and cost-effective model of opening “clinics-within-clinics” in which the Company proposes to partner with large care facilities to provide para-medical clinics inside the physical location of the primary care facility. This model results in a win-win for both Empower and the primary care facility partner as follows:

  • Substantially improved care for patients of the primary care facility
  • Significantly reduced start-up costs for Empower
  • Immediate access to the large patient base of the primary care facility
  • Immediate rental income for the primary care facility

With this proven winning model, the nationwide roll-out it is planned to commence immediately upon closing of the acquisition with expansion in the Greater Toronto Area, followed by expansion throughout Ontario and finally West through all Provinces with a standardized brand and technology platform.

Moreover, the acquisition includes incentives for the two Co-Founders of Momentum Health to open an additional 30 clinics across Canada.

CEO McAuley added “Having Dr. Rabinowitz and Dr. Tsimerman join me in leadership to rapidly expand Empower’s clinic footprint across Canada will be invaluable toward meeting our ambitious objectives.”

Momentum Co-Founder Dr. Robinowitz commented “Joining Empower provides us with the opportunity to scale an intricately designed health care model alongside the outstanding professionals currently on their team. This transaction will not only allow our current patients to have increased access to integrative care, we also strive to exponentially increase our patient base with strategic, nationwide expansion.”

Momentum Co-Founder Dr. Tsimerman commented “I am thrilled to be joining Empower Clinics with a shared vision of nationwide, truly integrative medical care based on patient – centric services. This unique opportunity allows us to provide an unparalleled patient experience and create a leading approach to modernized health care.”

TERMS OF ACQUISITION

Pursuant to the terms of the Agreement, Empower will pay the vendors of Momentum Health $275,000 cash at closing (including $44,648 to settle an outstanding debt of Momentum Health) with an additional $75,000 to be withheld as a holdback for adjustments, for an aggregate cash payment of $350,000. In addition, at closing, Empower will issue Dr. Jordan Rabinowitz and Dr. Aviv Tsimerman or their affiliates 5,128,204 common shares in the capital of Empower (at a deemed price of $0.0975 per share), 2,564,102 of which will be subject to contractual resale restrictions resulting in them being released quarterly from the date of closing in eight (8) equal instalments.

PERFORMANCE INCENTIVES TO OPEN 30 ADDITIONAL LOCATIONS

The acquisition also includes long-term performance incentives for Dr. Rabinowitz and Dr. Tsimerman. If, within 18 months from the closing date, the Company or its affiliates have opened and have operating an aggregate of ten (10) new clinic locations in Canada (“Milestone One”), each of Dr. Rabinowitz and Dr. Tsimerman shall be entitled to receive incentive stock options of Empower to purchase 1,875,000 common shares of Empower, vesting as follows:

  1. 1/3 immediately;
  2. 1/3 upon of the Company or its affiliates having opened and operating an aggregate of twenty (20) new clinic locations in Canada; and
  3. 1/3 upon of the Company or its affiliates having opened and operating an aggregate of thirty (30) new clinic locations in Canada.

ADDITIONAL DETAILS

Empower has agreed to enter into employment agreements with Dr. Rabinowitz and Dr. Tsimerman on closing of the acquisition, to lead the Canadian clinic expansion strategy.

Completion of the acquisition contemplated by the Agreement is subject to customary closing conditions which the Company anticipates being completed on or before December 21, 2020.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT EMPOWER:

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors:
Dustin Klein
Director
[email protected]
720-352-1398

Investors:
Steven McAuley
CEO
[email protected]
604-789-2146

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the Company’s nationwide rollout and timing and results of such rollout; the Company expecting the acquisition will provide Empower with a growing accretive business, as well as, a winning business model with plans for immediate expansion across the Greater Toronto Area, the province of Ontario and then nationwide in very rapid succession; the Company’s expectation for the costs of expansion; and the Company’s plans to partner with large care facilities to provide para-medical clinics inside the physical location of the primary care facility and the results of such model. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control; as well as those risk factors discussed or referred to in the Company’s disclosure documents filed with the securities regulatory authorities in certain provinces of Canada and available at www.sedar.com. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

$TGS.ca #Esports Announces Investment in Mountainside Games $DKNG $PENN $GAN $ESPO $AESE $EGLX.ca $BRAG.ca $FDM.ca

Posted by AGORACOM-JC at 3:11 PM on Thursday, December 17th, 2020
http://blog.agoracom.com/wp-content/uploads/2020/11/image-1.png
  • Completed an equity investment in a private esports company, Mountainside Games Ltd.
  • MSG hosts in person and online tournaments and handles all aspects of the events including registration, facilitation, and broadcasting.
  • MSG also creates unique Super Smash Bros content including Smash Talk, an online show available via YouTube.
  • MSG will operate out of the TGS office and work in collaboration with the TGS team on tournaments and events.
  • MSG will also use TGS to produce content for digital distribution, including existing property Smash Talk.

VANCOUVER, BC , Dec. 17, 2020 – TGS Esports Inc. (” TGS ” or the ” Company “) (TSXV: TGS) (FRA: 5RH) is pleased to announce that it has completed an equity investment (” Investment “) in a private esports company, Mountainside Games Ltd. (” MSG “).

MSG, led by Owner and CEO Martin Byerley , is a BC based organization that has a focus on tournaments and content within the Super Smash Bros community. MSG hosts in person and online tournaments and handles all aspects of the events including registration, facilitation, and broadcasting. MSG also creates unique Super Smash Bros content including Smash Talk, an online show available via YouTube. MSG will operate out of the TGS office and work in collaboration with the TGS team on tournaments and events. MSG will also use TGS to produce content for digital distribution, including existing property Smash Talk.

“Martin is one of the hardest workers I have met. His dedication to building MSG is second to none and he is primed to take MSG to the new heights. We are excited to be a part of his growth and provide the resources we have to help MSG get to the next level.” said Spiro Khouri , CEO of TGS “Adding a dedicated Smash Bros community to TGS is going to fill a gap we currently have. We also get to add MSG’s content to TGS’ growing library which brings a new element for our fans to engage in.”

“I am extremely excited for the opportunity to grow MSG to new heights. We have seen steady incremental growth over the past year and with the resources TGS brings to the table we can accelerate it greatly. I have had the chance to work with the TGS team over the past couple of months which has allowed me to do so much more, especially when it comes to content creation.” Said Martin Byerley “I can’t wait to devote even more time to the community!

Pursuant to an investment agreement dated December 16, 2020 (the ” Investment “), the Company subscribed for an aggregate of 3,333,334 common shares in the capital of MSG, representing approximately 25% of MSG, in consideration for aggregate cash consideration of $36,000 . In addition, under the Investment Agreement, subject to the approval of the TSX Venture Exchange (the ” TSXV “), the Company has also agreed to issue to MSG up to an aggregate of 40,000 common shares in the capital of the Company (” Milestone Shares “) at a deemed price equal to the Market Price (as defined in the policies of the TSXV) on the date of issue, upon the satisfaction of the following milestones by MSG within two years following the closing of the Investment:

  • 10,000 Milestone Shares on the date that MSG has hosted 24 tournaments co-streamed on the Company’s Twitch streaming channel;
  • 10,000 Milestone Shares on the date that MSG has published 24 episodes of their web series “Smash Talk”;
  • 10,000 Milestone Shares on the date that MSG has published 156 “Things You Should Know” videos to its YouTube channel; and
  • 10,000 Milestone Shares on the date that MSG has run 24 esports tournaments through an esports platform operated by the Company in its business.

About TGS Esports Inc.

TGS Esports Inc. is an organization focused on creating the ultimate esports experience. TGS is made up of industry professionals with 20+ combined years in the space of tournament organization, league facilitation, and production. This experience combined with the proposed acquisition of Pepper Esports Inc. allows TGS to offer a full suite of tools needed for any player or tournament organizer in esports. TGS is also the owner of Canada’s first dedicated esports arena, The Gaming Stadium, located in Richmond, British Columbia , which opened in June 2019.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

On behalf of the Board of Directors
Spiro Khouri
Spiro Khouri , CEO
TGS Esports Inc.

Disclaimer for Forward-Looking Information

Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the Company. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future, including with respect to: the potential benefits of the relationship between the Company and MSG resulting from the Investment, the satisfaction of the Milestones by MSG and the issuance of the Milestone Shares. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including risks related to factors beyond the control of the Company. The risks include the following: the unknown magnitude and duration of the effects of the COVID-19 pandemic and other risks that are customary to transactions of this nature. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them.

This press release is not an offer of the securities for sale in the United States . The securities have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an exemption from registration. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.

Avicanna $AVCN.ca $AVCNF Expands Distribution Network in South America Through Commercial Partnerships in Ecuador and Commercial Export of Feminized Seeds to Uruguay $KHRN.ca $TRUL.ca $VFF.ca

Posted by AGORACOM-JC at 7:39 AM on Thursday, December 17th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg
  • Partnership with Alliancepharma Technologies S.A., one of Ecuador’s largest pharmaceutical companies, will take advantage of the upcoming cannabis regulations to allow for the registration and distribution of several of Avicanna’s consumer and pharmaceutical products across Ecuador
  • Distribution agreement with Spenta S.A., an Ecuadorian cosmetic distributor, for the distribution of its derma-cosmetic product line branded as Pura Earth TM
  • Successful registration and export of CBD and CBG dominant feminized seeds to Uruguay from Colombia

TORONTO, Dec. 17, 2020 — Avicanna Inc. (“ Avicanna ” or the “ Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that it has entered into an importation and distribution agreement with Alliancepharma Technologies S.A. (“ Alliancepharma ”) for the distribution of Avicanna’s advanced and clinically supported medical and pharmaceutical formulations in Ecuador. Avicanna has also entered into an agreement with Spenta S.A. (“ Spenta ”), an Ecuadorian cosmetic distributor, for the distribution of its Pura Earth branded derma-cosmetic product line nationwide. As part of its commercial expansion plans, Avicanna has also completed an export of feminized seeds to Uruguay from its majority-owned cultivation subsidiary, Santa Marta Golden Hemp S.A.S. (“ SMGH’ ) in Santa Marta, Colombia.

Avicanna’s exclusive agreement with Alliancepharma will take advantage of the upcoming Ecuadorian regulations of cannabis-based products and allow for the registration and commercialization of Avicanna’s advanced cannabinoid-based consumer and pharmaceutical products in the Ecuadorian market. The product offerings include Avicanna’s deep tissue topical formulations marketed as consumer products in addition to several pharmaceutical products that are intended to be registered as indication specific drugs and natural medicines. Alliancepharma, a part of the Naturex group and one of the largest pharmaceutical companies in Ecuador, is expected to leverage its in-house distributionand commercialization capabilities as well as its network of nation-wide pharmacies to bring Avicanna’s products to consumers all over the country upon the regulations in Ecuador coming into effect.

“We are very excited to enter the Ecuadorian market with the first cannabinoid-based pharmaceutical products with the support of a world class partner such as Avicanna Inc. This partnership strengthens our commitment as pioneers and leaders in the pharmaceutical industry, offering innovative phyto-therapeutic solutions to continue improving the quality of life of our patients.” Stated Diego Vega, International Business Development Director of Alliancepharma.

Avicanna’s Pura Earth branded derma-cosmetic products are expected to enter the Ecuadorian market through Spenta’s distribution nationwide network of pharmacies, beauty retailers and e-commerce platforms. The agreement with Spenta coincides with an initial purchase order of several SKU’s which is expected to be exported from Colombia in Q1-2021. This will become the second South American market after Colombia in which the Pura Earth branded derma-cosmetic products will be available for sale. The derma-cosmetic formulations, which synergistically combine natural ingredients with hemp-derived CBD, have been developed through a rigorous scientific and evidence-based approach that includes positive results from the completion of 3 cosmetic human clinical studies.

As part of the Company’s commercial expansion plans, Avicanna’s majority owned subsidiary, SMGH, has completed the registration of its CBD and CBG dominant genetics in Uruguay and a commercial export of feminized non-psychoactive cannabis seeds to Uruguay. This marks three countries in which Avicanna’s seeds are currently commercially sold including the United States and Colombia. As a global cannabis and hemp cultivation industry begins to emerge, Avicanna’s industry leading genetics program seeds business unit is well positioned to be a reliable supplier of high quality seeds.

Lucas Nosiglia, President of Avicanna LATAM, commented: “We continue to demonstrate leadership across the LATAM markets and validate our diverse business model which is dedicated to quality cannabinoid products across the full value chain. We are optimistic about the opportunity in LATAM markets as we continue to see the regulations and business opportunities evolve and believe our medical and scientific superiority combined with our sustainable and economical costs positions us at the forefront of this emerging sector.”

To the knowledge of the Company, it is in compliance with all applicable laws in the jurisdictions in which it operates.

About Avicanna Inc.

Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development, and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.

Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna’s team of experts have developed and commercialized several industry leading product lines, including:

  • Pura Earth™ or Pura H&W™: an advanced and clinically tested line of CBD consumer derma-cosmetic products; and,
  • RHO Phyto™: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all 2 developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data.

With ongoing clinical trials on its derma-cosmetic (branded as Pura Earth or Pura H&W), medical cannabis (branded as RHO Phyto) and a pipeline of pharmaceutical products, Avicanna’s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception. Furthermore, Avicanna’s commitment to education is demonstrated through its annual medical symposium, the Avicanna Academy educational platform, and the My Cannabis Clinic patient program through its subsidiary company.

Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia. Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna’s Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020, Avicanna made history with a shipment of hemp seeds to the United States of America by completing the first ever export of hemp seeds from Colombia.

SOURCE Avicanna Inc.

Stay Connected

For more information about Avicanna, visit www.avicanna.com , call 1-647-243-5283, or contact Setu Purohit, President by email at [email protected] .

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and includes statements with respect to the ability of the Company to manufacture any of the products, the ability of the Company to export any of the products, the ability of Alliancepharma or Spenta to distribute the products, the regulations coming into full force and effect in Ecuador, and the ability of SMGH to continue to complete exporting cannabis seeds to Uruguay . Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated April 15, 2020 and final short form prospectus dated November 27, 2020, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com .

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Datametrex AI $DM.ca $DTMXF Ramps up COVID-19 Testing for Film & Television Sectors $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 7:22 AM on Thursday, December 17th, 2020
  • As of this coming January 2021, the Company has received order for an additional 3 film & TV productions in Toronto and an additional 6 l film & TV productions in Vancouver.
  • The Company is currently providing services to 6 production companies in Toronto and 11 production companies in Vancouver, administering approximately 6,000 tests per week.
  • The Company expects this will increase significantly with the additional projects which is seeing in its project pipeline.

Toronto, Ontario–(December 17, 2020) – Datametrex AI Limited  (TSXV: DM) (FSE: D4G) (OTC: DTMXF) (the “Company” or “Datametrex”) wishes to provide an update on film and television industry testing and lab facilities projects which it is undertaking in Canada.

As of this coming January 2021, the Company has received order for an additional 3 film & TV productions in Toronto and an additional 6 l film & TV productions in Vancouver. The Company is currently providing services to 6 production companies in Toronto and 11 production companies in Vancouver, administering approximately 6,000 tests per week. The Company expects this will increase significantly with the additional projects which is seeing in its project pipeline.

Datametrex has ramped up testing lab facilities in Vancouver. The lab now has a capacity of processing up to 10,000 COVID-19 tests per week with the ability to expand this capacity even further (if required).

Vancouver is the third-largest production centre in North America, worth CDN $3.2 billion during 2018/19, according to Creative BC. British Columbia is home to several world-class Film and TV studios, including Bridge Studios, Mammoth Studios, Vancouver Film Studios, North Shore Studios, Ironwood Studios, Canadian Motion Picture Park, and The Crossing Studios. (Source: CreativeBC Film Commission)

Entire film and TV production in Canada represent $8.92 billion in production volume, and full-time equivalent jobs represent 179,000 workers. In March 2020, the industry stopped worldwide and in Vancouver which represents 37% of Canadian productions, and the surrounding areas had 46 productions filming which does not include the TV commercial market. Each of the shows would have a minimum of a 100-person film crew. (Source: CreativeBC Film Commission)

The next largest film and television market is Ontario which represents 34% of Canadian productions and in 2019, Toronto’s film and television industry directly employed more than 28,000 people representing $3.17 billion in production volume. (Source: CreativeBC Film Commission)

“With Vancouver and Toronto feature-length movies and episodic series productions filming quickly ramping up, we feel that this will only expand the COVID-19 screening business for the film and TV industries,” said Marshall Gunter CEO of the Company.

About Datametrex

Datametrex AI Limited is a technology-focused with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at www.datametrex.com.

For further information, please contact:
Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

Certain statements including in this news release contain “forward-looking information” or constitute “forward-looking statements” within the meaning of applicable securities laws. Such forward-looking statements or information are provided for the purpose of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy, including the dollar amount of revenue anticipated under the Agreement.

Forward-looking statements or information are based on current expectations, estimates and projections that involve several risks and uncertainties, which could cause actual results to differ materially from those anticipated by the Company and described in the forward-looking statements or information. These risks and uncertainties may cause actual results to differ materially from the forward-looking statements or information.

Readers are cautioned that the foregoing list is not exhaustive of all possible risks and uncertainties. Readers are also cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations, and opinions of management on the time such forward-looking information is made. Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

MEDIA: The doctor will stream you now: How Binovi $VISN.ca $BNVIF is leading the charge in virtual vision therapy $EYPT $KALA $PTON $WELL.ca $DOC.ca $DOCRF

Posted by AGORACOM-JC at 4:27 PM on Tuesday, December 15th, 2020
  • The pandemic has created a new consumer expectation for virtual services
  • Tech company Binovi gives optometry patients a new alternative
  • With Binovi Connect, the company has created a seamless network for vision care professionals to work together

With 2020 becoming the year of the homebody, we’ve all had to drastically reduce our trips out of the house. While it’s been hard on everyone, we can consider ourselves lucky that there were already numerous resources to ease the transition into sheltering in place.

It’s no secret that companies bridging the distance between services like food delivery apps, and 24-hour product distribution have been the trend for a while now. Still, with communities shutting down, many newer services crossed the line from following the trend into being embedded into daily life.

While things like Zoom conferences and virtual personal training have been an infrequent occurrence pre-pandemic, consumers have realized that they’re now mainstream and accepted options to save time and social distance.

Office groups are even doing video-streamed murder mystery parties in place of their traditional in-person Christmas gatherings. It’s a new language of behaviour that we’re becoming fluent in as we continue to adapt to how COVID has changed our lives.

Even as restrictions lift and the curve eventually flattens, it’s hard to see a future without these new tools at consumers’ disposal. For instance, who would want to go back to sitting in a crowded waiting room, when you could simply have an online conference with your doctor? This Binovi Platform allows users to browse from a list of Binovi Providers, schedule appointments, conduct screening, and more.

It’s a shift that has already changed the healthcare industry. Specialist professionals can now maximize their patient schedule and keep appointments as socially distanced as possible. While it’s a handy change of pace, there has already been an opportunity to create a more accessible network to maximize efficiency and accuracy for both doctors and patients.


“Once a training regimen is established, along with a schedule for check-ins and evaluations, users can conduct their own training sessions.”

— Adam Cegielski, CEO, Binovi Technologies Corp.


Binovi offers the patient management resource that medical professionals have been waiting for

With one in four people worldwide living with issues related to vision that go beyond visual acuity, it’s time to address this gap and come up with an effective and efficient way for specialists to meet with patients during the pandemic and beyond.

Enter Binovi Technologies (TSXV: VISN | OTCQB: BNVIF), a best-in-class neuro-visual performance platform designed to test, analyze, track, and report on individual cognitive performance.

Established to enhance how optometrists work with their patients and bring treatment into the 21st century, Binovi is supported by recognized optometry leaders worldwide.

This connection to vision therapists, occupational therapists, and physical therapists has led the company towards innovative testing methods that patients can do remotely. While in the presence of a professional, patients produce quantifiable data that Binovi can analyze, consult with other professionals about, and recommend the next steps for treatment.

Binovi’s experience with facilitating a channel between professionals and patients has led to the company’s latest telehealth innovation, Binovi Connect, which is a web-based video conferencing solution that connects consumers to vision care professionals focused on concussions, reading skills, and athletic enhancement.

The new application not only gives a straightforward service to both parties, but it provides a network for professionals to consult and collaborate with each other about specific patient treatments. It’s a streamlining of service that gives clarity and peace of mind to anyone who has felt like they might not have grasped everything their doctor has just said.

Patients can easily choose from specialists who best meet their needs, establish a routine with their selected one, and monitor in real-time the results they’ve made. On the other side of things, doctors can see notes from other professionals and collaborate on multiple fronts to create multi-tiered treatment tactics for shared patients.

It’s a program that has countless applications in the healthcare world, but for the moment, Binovi is remaining focused on vision-based therapy. With 800 clinics across the globe already using Binovi’s systems, their market share of the $74 billion a year Visioncare industry will only grow.
 

To do that, the company emphasizes the program’s ease of use and a clear value proposition. Binovi Connect is incredibly user-friendly, and patients are given everything they need to create progress.

“Once a training regimen is established, along with a schedule for check-ins and evaluations, users can conduct their own training sessions,” says Cegielski.

“This is happening while still under the watchful eye of their healthcare professionals who can monitor the results with session data stored in the cloud.”

Since the launch of this platform, the 800 organizations have created nearly 31,000 users, together completing more than 400,000 active sessions centered around the Binovi Library list of activities.

Niche treatments for niche ailments

When it comes to niche treatments, Binovi offers patients the materials they need as recommended by each doctor for treatment. This could be equipment for equilibrium building exercises or the means to conduct a supervised vision test.

Binovi Coach encourages and empowers patients to confidently complete their prescribed home therapy with clarity and guidance.

The insights from these sessional treatments are then boosted by the program’s AI. Cloud-based session data is effectively merged with data from the clinicians’ past findings, then offered to each patient’s current therapist. This allows each session to produce real-time suggestions, and present immediate resources to each therapist.

It’s a groundbreaking new approach to treatment, that has produced startling results for patients suffering from concussions, binocular vision dysfunction, amblyopia, and countless other afflictions. With Binovi, patients can actively improve dynamic visual acuity, visual reaction time, depth perception, and hand-eye/body-eye coordination.

The framework is already in place for patients to receive the specialized care they need regardless of geography or time zone. Now, it’s just a matter of time before consumer standards for virtual appointments and personal care reach a tipping point. Determining whether someone needs vision therapy, or could benefit from vision training, can start early.

When that happens, Binovi is ready to serve.

So, what’s next for the platform?

  • Migrating offline sessions to Binovi Connect
  • Inclusion of a broader class of providers
  • Support for more languages
  • Release of SDK for integration with other platforms
  • Anonymized data access for research
  • Expecting to launch a Beta version of the app by fiscal Q1 2021

“We are excited to continue to build out a robust telehealth platform as we continue our mission to be the leader in neuro-vision performance technology space.”

Why should investors take note of Binovi?

Binovi’s future innovation opportunities are largely driven by identifying high-value client needs and evaluating each unique opportunity to develop new products and services in the areas of neurotechnology and vision training to support unlocking human performance.

The company’s future innovation pipeline looks like this:

  • Expanding its capabilities within the education sector
  • Partnering with elite athletes, professional sports as well as esports teams
  • Standardizing data collection in the field to create optimized training regimens based on unique profiles, peer groups and custom goals
  • Working with military and law enforcement
  • Treating the aging population and improving performance for those affected by the impact of brain-related diseases or natural aging

Binovi’s innovation milestones from first acquiring Wayne Engineering in 2015 and its educational IP to commercializing its Binovi Connect Platform.

Additionally, the acquisition and integration of the VIMA Rev Strobe Lenses under the Binovi umbrella has provided Binovi with an additional toolset to expand its offering. Developed by Nike’s former Global Director of Vision Science and his team of sport science experts, the VIMA Rev Strobe Lenses are an integrated strobe training system that stimulates neuro-cognition through vision training.

VIMA’s technology is being integrated into Binovi’s product platform, with several orders already fulfilled. Current VIMA Rev strobe users include the NHL’s Colorado Avalanche, the NBA’s Golden State Warriors, Chicago Bulls and the Milwaukee Bucks.

Binovi has had a tremendous year so far, and they’re not done yet.

To learn more about the company, visit their website here.

Follow Binovi Technologies on social media:

Facebook
Twitter
LinkedIn
Instagram

Source: https://www.bnnbloomberg.ca/the-doctor-will-stream-you-now-how-binovi-is-leading-the-charge-in-virtual-vision-therapy-1.1536215

AGORACOM Welcomes Valeo Pharma $VPH.ca $VPHIF With 7 Products To Be Launched In 2021 / 2022 ($45M. Estimated Peak Sales / Year) $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 3:31 PM on Tuesday, December 15th, 2020

(VPH: CSE) (VPHIF: OTCQB) (VP2: FSE)

www.valeopharma.com

Why Valeo Pharma?

  • Commercial stage revenue generating Canadian pharmaceutical company
  • Approaching EBITDA positive in coming months
  • 9 products currently marketed ($40M. estimated peak sales / year)
  • 7 additional products in pipeline ($45M. estimated peak sales / year)
  • In-license business model, no development or clinical risk
  • $1.5M in quarterly revenue ending July 31, 2020
  • $5.26M in revenue for 9 months ending July 31, 2020

What Exactly Does Valeo Pharma Do?

  • Acquires Canadian rights to commercial stage, innovative and proprietary drugs
  • Commercializes innovative prescription products in Canada
  • Focused on Neurodegenerative Diseases,  Oncology and Hospital Specialty Products
  • Internally manages portfolio through all stages of commercialization

Commercial Portfolio

VPH-Commercial-Portfolio

Here’s just a few products already approved:

BRAND: REDESCA® (BIOSIMILAR)

Launch: Q1-2021

Status: Approved by Health Canada December 2020

Indication: Injectable blood thinner

Market size:  $200M

Peak sales estimate $30 – $40M, sales margin 55 – 60% https://www.youtube.com/embed/XNn29Cx2ToY

BRAND: HESPERCOTM

Launch: Launched in Q4 -2020

Status: Approved by Health Canada

What is it: Anti-Oxidant – Immune system support

How’s it sold: Retail, Online (www.hesperco.com, www.amazon.ca)

Market Size: $500M

hesperco

BRAND: ONSTRYV®

Launch: Q3 2019

Status: Received positive recommendation for public reimbursement in Quebec

Use: Parkinson’s disease, 1st treatment launched in Canada since 2006

Patient base: 100,000 in Canada 2nd chronic neurodegenerative disorder after Alzheimer

Market Size: $20M

%Peak sales estimate $8M, sales margin 65-70 %

Pipeline

Pipeline

The Valeo Model

Company Forecast

  • All portfolio & pipeline products to be on the market by end 2022
  • Solid pipeline composed of “licensed” products
  • Peak Sales reached 2-4 years after market launch
  • From 1 product on the market to 12 in 4 years and more to come
  • Forecast excludes any new product licensing

Hub On AGORACOM / Corporate Profile

VIDEO – Mountain Valley MD $MVMD.ca Catches Small Cap Fire After #Ivermectin Testimony In US Senate Called “Miraculous Effectiveness” In Prohibiting Transmission Of #COVID-19

Posted by AGORACOM-JC at 4:19 PM on Monday, December 14th, 2020

“It basically obliterates transmission of this virus”  

This was the testimony of  Pierre Kory, M.D., Associate Professor of Medicine at St. Luke’s Aurora Medical Center, delivers passionate testimony during the Senate Homeland Security and Governmental Affairs Committee hearing on “Early Outpatient Treatment: An Essential Part of a COVID-19 Solution, Part II.”

We interviewed Leigh Hughes, newly appointed Advisor to MVMD who will be supporting the Company in the areas of M&A, corporate finance and pharmaceutical licensing, to provide us with further insight as to why the testimony of Dr. Kory is so relevant to MVMD … and why Dr. Kory actually called MVMD last week to discuss the Company’s involvement with Ivermectin.

Mountain Valley MD has traded over 50,000,000 shares in the last 3 trading days, so there is a clear need for information amongst retail investors.